News & Events
Press Releases
In the News
View news archiveOur Perspectives
Nimbus CEO Jeb Keiper was a featured guest at ENDPOINTS@JPM24, where he discussed how Nimbus has been able to successfully navigate the biotech capital markets and provide unquestionable return to investors by developing and partnering breakthrough medicines. Video of Jeb’s full session is available on-demand at the link below (registration required for viewing).
The Book of Nimbus is still being written, but its arc over the years already shows the shape of what I believe to be Nimbus’ mark on our industry: as an R&D powerhouse with the potential to repeatedly create breakthrough medicines for patients.
Like many middle-aged weekend warriors, I’ve been recently sidelined by injury simply through doing what I’ve regularly done: run. Injury stopped me from running last fall and I’ve since seen orthopods and running experts galore.
But it’s been the physical therapists who’ve really laid the hammer home: “Jeb, you need to work on your core.”
Nimbus CEO Jeb Keiper was a featured guest at ENDPOINTS@JPM24, where he discussed how Nimbus has been able to successfully navigate the biotech capital markets and provide unquestionable return to investors by developing and partnering breakthrough medicines. Video of Jeb’s full session is available on-demand at the link below (registration required for viewing).